Tuesday, November 19, 2013
• Esperion Therapeutics Inc., of Plymouth, Mich., reported results from a Phase III trial of ETC-1002 for patients with hypercholesterolemia and a history of statin intolerance showing that the drug lowered LDL-C compared to placebo by an average of 32 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.